Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2026 (Report No. 3)
Date of Filing: March 11, 2026
This filing reports a significant regulatory milestone: the U.S. FDA approval of the Company's post-marketing "ChoICE" study for ProSense® Cryoablation in the local treatment of low-risk breast cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on a specific regulatory event and does not contain financial statements or performance data.
Material Changes
Regulatory Approval: The U.S. FDA has approved the "ChoICE" post-marketing study for the ProSense® Cryoablation system. This represents a material development in the Company's clinical and commercial strategy for low-risk breast cancer treatment.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the FDA approval. Specific management commentary on financial outlook or guidance is not included in the text of this Form 6-K.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard incorporation by reference into existing registration statements.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the "ChoICE" study design and timeline.
- Review the Company's most recent Form 20-F or quarterly reports for current financial health, as this filing contains no financial data.
- Confirm the status of the ProSense® Cryoablation system's commercialization in the U.S. market following this approval.
- Check for any subsequent filings that may supersede the information incorporated by reference in this report.